ArticleFrontiers in immunology2026
Integrated multi-omics analysis indicates MARCO and ZBTB20 as candidate biomarkers in rheumatoid arthritis and tuberculosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) patients have a clearly increased possibility to develop tuberculosis (TB). However, the common molecular background, useful diagnostic molecules, and treatment-related targets of this comorbidity are still not sufficiently explained. We attempted to search the shared genetic factors and candidate drug targets for RA and TB by an integrated multi-omics way. Methods: Bulk transcriptome data sets for RA and TB were obtained from Gene Expression Omnibus (GEO). Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were first performed to collect overlapped disease-related genes. Least Absolute Shrinkage and Selection Operator (LASSO) regression was then applied to select hub genes. External data sets, single-cell RNA sequencing (scRNA-seq), and quantitative real-time PCR (qRT-PCR) using clinical samples were used for validation. We also carried out immune infiltration analysis, gene set enrichment analyses, molecular docking, and 100 ns molecular dynamics (MD) simulation, in order to describe possible function and treatment value of these genes. Results: A total of 312 co-expressed genes common to RA and TB were obtained, and these genes were mainly gathered in immune and inflammatory processes. Conclusions: Our study suggests that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.